ArticleEndocrine connections2025
A high FT3 level might protect bone mineral density among euthyroid type 2 diabetes mellitus patients.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Thyroid hormones and thyroid hormone sensitivity indices correlate with volumetric bone mineral density and vertebral fracture risk among the osteoporotic population in northern China.Frontiers in endocrinology · 2026Article
- Association of impaired sensitivity to thyroid hormone with low bone mineral density and bone mineral content.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This research was to investigate the relationship among thyroid function, sensitivity to thyroid hormone indices, and bone mineral density (BMD) in euthyroid individuals with type 2 diabetes mellitus (T2DM). Methods: A total of 536 euthyroid patients with T2DM were included. The subjects were measured for anthropometric parameters, biochemical indicators, and clinical characteristics. Their bone density was tested by dual-energy X-ray, and then they were classified according to their outcomes. Results: In comparison to the normal BMD group, the FT3 level was notably reduced in the low BMD groups (P < 0.05). The patients were sequentially assigned to tri-sectional quantiles according to FT3. Compared with tertile 1, patients in tertile 2 had a higher value of BMD. Spearman correlation analysis showed that the FT3 level was positively associated with BMD. After adjustment in multiple linear regression, FT3 level remained significantly related to decreased BMD. A significant independent association between FT3 and BMD was found by multiple logistic regression analysis after adjusting for potential confounding variables (OR = 0.187, P < 0.05). No significant relation was found between thyroid hormone indices and BMD. Conclusion: FT3 level was independently associated with BMD in euthyroid patients with T2DM. High-normal FT3 may be a protective factor for BMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.